Merck says its oral PCSK9 inhibitor ‘significantly’ cut cholesterol in two Phase 3 trials
Merck’s drug candidate for high cholesterol has succeeded in two late-stage trials in different groups of patients, a milestone the company says should bring it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
